載入中
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
前收盤價
US$1.86
+US$0.15 · +8.77%
盤中時間採用ET。市場資料可能有所延遲。
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
日內區間
目前US$1.86
52週區間
目前US$1.86
盤中時間採用ET。市場資料可能有所延遲。
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
日內區間
目前US$1.86
52週區間
目前US$1.86
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 53.49萬 USD | 51.67萬 USD | 9.86萬 USD | 4.25萬 USD |
| 毛利 | — | −53.49萬 USD | −51.67萬 USD | −9.86萬 USD | −4.25萬 USD |
| 研究與開發 | 1342.18萬 USD | 961.55萬 USD | 1226.35萬 USD | 1023.24萬 USD | 275.4萬 USD |
| 銷售、一般及管理費用 | 577.11萬 USD | 551.04萬 USD | 663.82萬 USD | 833.48萬 USD | 335.47萬 USD |
| 營業費用 | 2798.01萬 USD | 1512.58萬 USD | 1890.18萬 USD | 1856.72萬 USD | 610.87萬 USD |
| 利息收入 | 7.92萬 USD | 684 USD | 5285 USD | 2.04萬 USD | 664 USD |
| 利息支出 | 6616 USD | 2.68萬 USD | 5.59萬 USD | 1756.5萬 USD | 9.51萬 USD |
| 折舊和攤銷 | 11.42萬 USD | 53.49萬 USD | 51.67萬 USD | 9.86萬 USD | 4.25萬 USD |
| 營業利益 | −2798.01萬 USD | −1566.07萬 USD | −1941.85萬 USD | −1866.58萬 USD | −615.11萬 USD |
| 淨利 | −3466.11萬 USD | −1675.5萬 USD | −1854.61萬 USD | −1756.5萬 USD | −684.34萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
